Company Description
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL).
In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc).
The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 11, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 152 |
| CEO | David Chang |
Contact Details
Address: 210 East Grand Avenue South San Francisco, California 94080 United States | |
| Phone | 650 457 2700 |
| Website | allogene.com |
Stock Details
| Ticker Symbol | ALLO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001737287 |
| CUSIP Number | 019770106 |
| ISIN Number | US0197701065 |
| Employer ID | 82-3562771 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David D. Chang M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder and Executive Chairman |
| Joshua A. Kazam | Co-Founder and Director |
| Dr. Zachary J. Roberts M.D., Ph.D. | Executive Vice President of Research and Development and Chief Medical Officer |
| Geoffrey M. Parker | Executive Vice President and Chief Financial Officer |
| Benjamin M. Beneski | Senior Vice President and Chief Technical Officer |
| Earl M. Douglas Esq. | Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary |
| Susan R. Lundeen | Chief People Officer |
| Christine Cassiano | Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer |
| Annie Yoshiyama | SVice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2026 | SCHEDULE 13G | Filing |
| Apr 21, 2026 | 144 | Filing |
| Apr 20, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 15, 2026 | 8-K | Current Report |
| Apr 15, 2026 | 424B5 | Filing |
| Apr 13, 2026 | 424B5 | Filing |
| Apr 13, 2026 | 8-K | Current Report |
| Apr 13, 2026 | 8-K | Current Report |
| Apr 1, 2026 | 144 | Filing |
| Mar 16, 2026 | 144 | Filing |